| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Graphite Bio, Inc. | CHIEF BUSINESS OFFICER | Common Stock | 299,941 | $1,223,759 | $4.08 | 11 Apr 2022 | Direct |
| Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 4,718 | 30 Sep 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LENZ | Graphite Bio, Inc. | 11 Apr 2022 | 1 | +$20,050 | 4 | CHIEF BUSINESS OFFICER | 13 Apr 2022, 19:35 |
| LENZ | Graphite Bio, Inc. | 16 Feb 2022 | 1 | $0 | 4 | CHIEF BUSINESS OFFICER | 18 Feb 2022, 17:56 |
| AVTX | Avalo Therapeutics, Inc. | 01 Dec 2021 | 0 | $0 | 4 | Director | 03 Dec 2021, 19:36 |
| AVTX | Avalo Therapeutics, Inc. | 30 Sep 2021 | 1 | $0 | 4 | Director | 04 Oct 2021, 16:45 |
| AVTX | Cerecor Inc. | 30 Jun 2021 | 1 | $0 | 4 | Director | 02 Jul 2021, 16:06 |
| LENZ | Graphite Bio, Inc. | 24 Jun 2021 | 0 | $0 | 3 | CHIEF BUSINESS OFFICER | 24 Jun 2021, 21:16 |
| AVTX | Cerecor Inc. | 15 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 16:41 |
| LENZ | Graphite Bio, Inc. | 13 Jan 2021 | 10 | +$148,093 | 4 | CHIEF BUSINESS OFFICER | 01 Jul 2021, 19:00 |